Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer

BACKGROUND: Many co-existing medical conditions may affect the outcome in patients treated with immune checkpoint inhibitors for advanced cancer. There is currently not any information on whether metabolic syndrome (MetS) impacts the clinical outcome in patients treated with immune checkpoint inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bou Zerdan, Maroun, Ashok Kumar, Prashanth, Barrios, Dulce M., Glidden, Alanna, Nasr, Dayana, Niforatos, Stephanie, Ghelani, Ghanshyam, Leibovitch, Jennifer, Nasr, Sandy, KC, Binod, Ombada, Mulham, Khokhar, Farzam, Poudyal, Bhavya, Bhandari, Jenish, Shahnawaz, Myera, Graziano, Stephen, Lim, Seah H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213668/
https://www.ncbi.nlm.nih.gov/pubmed/37251929
http://dx.doi.org/10.3389/fonc.2023.1134824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213668/
https://www.ncbi.nlm.nih.gov/pubmed/37251929
http://dx.doi.org/10.3389/fonc.2023.1134824

Ejemplares similares